Form 4: Adaptive Biotechnologies' Chief Scientific Officer Executes Stock Option and Sells Shares Under 10b5-1 Plan

Harlan S Robins, Chief Scientific Officer of Adaptive Biotechnologies, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Harlan S Robins, the Chief Scientific Officer of Adaptive Biotechnologies, executed a transaction involving the company's stock on March 24, 2025.
• The transaction involved the exercise of stock options to acquire 1,698 shares of common stock at a price of $6.32 per share.
• Simultaneously, Robins sold 1,698 shares of common stock at a weighted-average price of $9.00, with individual sales ranging from $9.00 to $9.01.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 26, 2024.
• Following these transactions, Robins directly owns 1,279,524 shares of Adaptive Biotechnologies common stock and holds options for 68,412 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy and do not necessarily reflect a change in the executive's outlook on the company.

Positives

• The use of a 10b5-1 trading plan suggests the transactions were pre-planned and not based on insider information at the time of the trade.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the use of a 10b5-1 plan mitigates this concern.

Industry Context

Executive stock transactions are common and closely monitored, especially in biotech companies where stock options are a significant part of compensation. The use of a 10b5-1 plan is a standard practice to avoid insider trading concerns.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry often include stock options and restricted stock units to align management's interests with those of shareholders.
• Trading activity by insiders is a common occurrence, and the use of 10b5-1 plans is a widely accepted practice to ensure compliance with securities laws.
• Comparing Adaptive Biotechnologies' executive compensation and trading activity with peers like Illumina, Inc. (ILMN) or Bio-Rad Laboratories (BIO) would provide a broader context.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares involved.

Key Dates

Keywords

Adaptive Biotechnologies, Harlan S Robins, stock options, 10b5-1 trading plan, executive stock sale, ADPT, Chief Scientific Officer